WB analysis of whole cell extracts (30 μg lysate) of U-87 MG (Lane 1), U-87 MG treated with 25 μg/mL anisomycin for 30 minutes (Lane 2), K562 (Lane 3), K562 treated with 25 μg/mL anisomycin for 30 minutes (Lane 4) using GTX24736 ATF2 (phospho Thr71) antibody.
Dilution : 1-2 μg/ml

IHC-P analysis of human breast carcinoma tissue using GTX24736 ATF2 (phospho Thr71) antibody.
Right : Primary antibody
Left : Negative control without primary antibody
Antigen retrieval : 10mM sodium citrate (pH 6.0), microwaved for 8-15 min
Dilution : 1:20

WB (peptide competition) analysis of Jurkat cells treated with 10 μg/mL anisomycin for 60 minutes using GTX24736 ATF2 (phospho Thr71) antibody prior incubated with the phosphopeptide immunogen (Lane 2), the non-phosphopeptide corresponding to the phosphopeptide immunogen (Lane 3), or a generic phosphothreonine-containing peptide (Lane 4) control. The data show that only the immunogen phosphopeptide blocks the signal, demonstrating the specificity of the antibody. The membrane treated with phosphatase (Lane 5) eliminates the signal further verifying that the antibody is phospho-specific.

IHC-P analysis of mouse brain tissue using GTX24736 ATF2 (phospho Thr71) antibody.
Right : Primary antibody
Left : Negative control without primary antibody
Antigen retrieval : 10mM sodium citrate (pH 6.0), microwaved for 8-15 min
Dilution : 1:20